Intermittent Versus Continuous Erlotinib with Concomitant Modified `Xelox' (Q3w) in First-Line Treatment of Metastatic Colorectal Cancer (Mcrc)
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2013
At a glance
- Drugs Erlotinib (Primary) ; Capecitabine; Oxaliplatin
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 01 Oct 2013 Results published in Cancer.
- 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.
- 01 Oct 2012 Primary endpoint 'Objective-clinical-response-rate' has been met.